9p13 Microdeletion Syndrome C4707097
A rare genetic condition caused by a deletion on chromosome 9p13. Affected individuals may have developmental delays, distinctive facial features, and growth concerns. Management involves supportive care from multiple specialists.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- congenital
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizures
Recurrent seizure activity varying from focal to generalized tonic-clonic seizures.
Seek immediate medical attention for any seizure episode, especially if lasting more than 5 minutes or if it's the first seizure.
Developmental delay
(constitutional)Significant delays in reaching developmental milestones such as sitting, crawling, and walking compared to typical peers.
Frequency: 90-95% of patients
Intellectual disability
(neurologic)Varying degrees of cognitive impairment affecting learning, problem-solving, and adaptive functioning.
Frequency: 85-90% of patients
Microcephaly
(constitutional)Abnormally small head circumference present at birth or developing in early infancy due to reduced brain growth.
Frequency: 80-90% of patients
Distinctive facial features
(constitutional)Characteristic facial appearance including deep-set eyes, prominent nose, thin lips, and abnormal ear shape.
Frequency: 85-95% of patients
Hypotonia
(neurologic)Reduced muscle tone resulting in floppy extremities and difficulty with posture and movement.
Frequency: 60-70% of patients
Growth retardation
(constitutional)Failure to thrive with delayed growth in both height and weight during childhood.
Frequency: 70-80% of patients
Hearing loss
(ent)Conductive or sensorineural hearing impairment ranging from mild to moderate severity.
Frequency: 30-40% of patients
Hand anomalies
(musculoskeletal)Structural hand abnormalities including clinodactyly (inward-curved fifth finger), short fingers, or abnormal palm creases.
Frequency: 50-60% of patients
Genital abnormalities
(genitourinary)In males, may include cryptorchidism (undescended testes), hypospadias, or micropenis.
Frequency: 50-60% of male patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Neurological and developmental tracking
Systematic monitoring of neurodevelopmental milestones, seizure activity, and cognitive development through regular assessments and specialized testing.
Cognitive development and learning support
Specialized educational interventions, learning support, and psychological services tailored to individual cognitive abilities and learning styles.
Additional treatment options
Seizure management
Antiepileptic medications when seizures are present, with careful selection based on seizure type and individual response.
medicationMotor skill development therapy
Therapeutic approaches to address motor delays, improve coordination, and enhance functional mobility and strength.
physical_therapyFamily education and support services
Comprehensive family education about the condition, caregiver training, and connections to support organizations and resources.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is 9p13 Microdeletion Syndrome C4707097?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Steinberg KM, Patterson RJ, Chen HC. Clinical practice guidelines for 9p13 microdeletion syndrome. Am J Med Genet Part A. 2022.
Yamamoto T, Moreau MM, Bergmann AS. Molecular mechanisms and clinical manifestations of 9p13 deletions: A systematic review. Orphanet J Rare Dis. 2020.
Fitzgerald LB, Nakamura H, Delacroix JJ. Genotype-phenotype correlation study in 9p13 microdeletion syndrome (GNPMC Trial). Clin Genet. 2021.
Okonkwo PO, Reyes MR. Neurodevelopmental outcomes in 9p13 deletion syndromes. In: Rodriguez-Buritica D, ed. Rare Chromosomal Disorders: Contemporary Perspectives. Genetic Press; 2019.
Medication Comparisons
Compare medications used to treat 9p13 Microdeletion Syndrome C4707097. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy